Articles related to EVIDENCE REVIEW

Creatine supplementation showed mixed effects on depressive symptoms across five randomized trials involving patients with mood disorders. The early findings suggest potential adjunctive benefit in some populations but do not establish a consistent treatment effect.

A network meta-analysis of 32 randomized trials found long-term, high-dose vitamin D supplementation added to standard multiple sclerosis therapy reduced relapse risk and eased disability progression, while short-term use showed no significant effect.

A Bayesian network meta-analysis of 31 randomized trials found aerobic, combined, and high-intensity interval training each associated with reductions in 24-hour ambulatory systolic blood pressure compared with control conditions, with no modality demonstrating clear superiority and all comparisons rated very low to low confidence.

AREDS2 remains the evidence-based standard for AMD supplementation, but expanding understanding of complement dysregulation, mitochondrial dysfunction, and macular carotenoid biology has prompted discussion about whether a next-generation formulation could address pathways the current one does not target.

A network meta-analysis of 15 randomized trials found that no pharmacologic treatment outperformed placebo for MS-related fatigue severity, though amantadine and fampridine showed statistically significant and potentially clinically meaningful improvements in fatigue-related daily functioning.

A network meta-analysis of 716 randomized trials and 159,362 participants found ARB-based regimens had the lowest rates of treatment discontinuation due to adverse effects, with the ARB-CCB combination ranking as the best-tolerated dual-drug option among antihypertensive regimens examined.